Click on image to view larger version.

Figure 7 Hemodynamic effects of the selective endothelin_A (ET_A)-receptor antagonist darusentan after oral administration in moderate congestive heart failure. Darusentan caused a dose-dependent decrease in systemic and pulmonary vascular resistance, whereas cardiac index increased. Plasma catecholamines and heart rate did not change. (Modified from [223]).